{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Latest Advances in the Prevention and Control of Chemotherapy-induced Nausea and Vomiting - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"0P2o0TOe8h\"><a href=\"https:\/\/themedicalxchange.com\/en\/2010\/10\/08\/the-35th-european-society-for-medical-oncology-esm\/\">Latest Advances in the Prevention and Control of Chemotherapy-induced Nausea and Vomiting<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2010\/10\/08\/the-35th-european-society-for-medical-oncology-esm\/embed\/#?secret=0P2o0TOe8h\" width=\"600\" height=\"338\" title=\"&#8220;Latest Advances in the Prevention and Control of Chemotherapy-induced Nausea and Vomiting&#8221; &#8212; The Medical Xchange\" data-secret=\"0P2o0TOe8h\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2010\/10\/ESMO_graph1_en.png","thumbnail_width":792,"thumbnail_height":595,"description":"Milan \u2013 Dramatic progress has occurred over the past three decades in the management of chemotherapy-induced nausea and vomiting (CINV). Control rates have increased from 0-10% in 1980 to 75-85% in 2010. Still, many cancer patients endure unnecessary bouts of emesis due to inadequate prophylactic treatment. Nausea complicates an even greater proportion of chemotherapy cycles, as less progress has occurred in controlling that adverse effect as compared with vomiting. With currently available medications, clinicians have the means to eliminate CINV, which should be the goal for every cancer patient who requires chemotherapy. Adherence to clinical guidelines offers the potential to achieve the goal of preventing nausea and vomiting in every cancer patient who receives chemotherapy. Recent updates of guidelines have increased emphasis on use of NK1 antagonists as an essential component of strategies to prevent and control CINV in cancer patients."}